The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aratana Therapeutics, Inc. | Common | 03874P101 | 900 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| Chiasma, Inc. | Common | 16706W102 | 29,829 | 5,736,296 | SH | SOLE | 5,736,296 | 0 | 0 | ||
| Conatus Pharmaceuticals, Inc. | Common | 20600T108 | 2,662 | 2,464,807 | SH | SOLE | 2,464,807 | 0 | 0 | ||
| Harpoon Therapeutics, Inc. | Common | 41358P106 | 42,846 | 4,524,425 | SH | SOLE | 4,524,425 | 0 | 0 | ||
| Rhythm Pharmaceuticals, Inc. | Common | 76243J105 | 84,283 | 3,074,893 | SH | SOLE | 3,074,893 | 0 | 0 | ||
| Syndax Pharmaceuticals, Inc. | Common | 87164F105 | 11,386 | 2,168,691 | SH | SOLE | 2,168,691 | 0 | 0 | ||
| TCR2 Therapeutics, Inc. | Common | 87808K106 | 70,607 | 4,050,865 | SH | SOLE | 4,050,865 | 0 | 0 | ||